A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo‐Bermejo, Violeta Serra(Vall d'Hebron Institute of Oncology), Benedetta Pellegrino(University of Parma), Cristina Cruz(Vall d'Hebron Institut de Recerca), Vicente Peg(Instituto de Salud Carlos III), Albert Gris‐Oliver, Mandy Ducy(Centre hospitalier de l'Université Laval), Judit Grueso(University of North Carolina at Chapel Hill), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Isabel T. Rubio(Clinica Universidad de Navarra), J. Carl Barrett(National Institute of Environmental Health Sciences), Olga Rodríguez(University of North Carolina at Chapel Hill), Javier Cortés(Villa Maria Hospital), Xavier Serres, Olivier Déas, Mark J. O’Connor(AstraZeneca (United Kingdom)), Jacques Simard(Université Laval), Jean‐Gabriel Judde, Alejandro Moles‐Fernández(Vall d'Hebron Institute of Oncology), Jos Jonkers(The Netherlands Cancer Institute), Sara Gutiérrez‐Enríquez, Stefano Cairo, Alba Llop‐Guevara(Vall d'Hebron Institut de Recerca), Alejandra Bruna(Institute of Cancer Research), Jean‐Yves Masson(Université Laval), Graham Dellaire(Dalhousie University), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Cristina Saura(Vall d'Hebron Hospital Universitari), Cristina Viaplana(Vall d'Hebron Institute of Oncology), Judith Balmañà(Vall d'Hebron Hospital Universitari), Sandra Bonache, Marta Guzmán(University of North Carolina at Chapel Hill), Rodrigo Dienstmann(Universitat de Vic - Universitat Central de Catalunya), Carlos Caldas(University of Cambridge), Patricia Gómez(Universitat Autònoma de Barcelona), Yasir H. Ibrahim(Royal National Orthopaedic Hospital), Orland Dı́ez(Vall d'Hebron Hospital Universitari), José Baselga(Harvard University), María Vidal(Inserm)
Cited by 271
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k